Biocodex SAS Announces License of Exclusive rights for Diacomit® (Stiripentol) with Excelsior Biopharma Inc.
Biocodex and Excelsior Biopharma Inc. have signed an exclusive licensing agreement for the Taiwanese market for Diacomit® (stiripentol). Diacomit® is an antiepileptic drug approved for adjunctive treatment in Dravet syndrome also known as severe myoclonic epilepsy in infancy (SMEI). Dravet syndrome is a severe infantile-onset and highly treatment-resistant epileptic encephalopathy that is thought to affect approximately 1 in 20,000 individuals.
“We are pleased to have entered into this collaboration with Excelsior Biopharma Inc. which is a step forward to Diacomit development in Asia. We remain committed to bringing a new treatment option to Dravet patients in Taiwan and address unmet needs of these patients suffering from one of the most resistant forms of early onset epilepsy” says Nicolas Coudurier, CEO of Biocodex.
The addition of Diacomit® to the Excelsior Biopharma Inc. portfolio further reinforces the company’s position as a major player in the CNS space.
“Excelsior Biopharma Inc. has devoted into the business of rare diseases and in the field of central nervous system including flexor spasm, spasticity, epilepsy, essential tremor for more than 3 decades since 1986. We are very glad to register Diacomit for Dravet syndrome in Taiwan market to expand our service in children epilepsy… ” said Joseph Chen, Excelsior Biopharma’s CEO.